CHF10.52
1.50% yesterday
SIX Swiss Exchange, Jun 13, 05:31 pm CET
ISIN
CH1129677105
Symbol
MEDX
Sector

Medmix Target price 2025 - Analyst rating & recommendation

Medmix Classifications & Recommendation:

Buy
100%

Medmix Price Target

Target Price CHF15.50
Price CHF10.52
Potential
Number of Estimates 2
2 Analysts have issued a price target Medmix 2026 . The average Medmix target price is CHF15.50. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 2 analysts: 2 Analysts recommend Medmix to buy, 0 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Medmix stock has an average upside potential 2026 of . Most analysts recommend the Medmix stock at Purchase.

Sales and Margin forecast 2025, 2026 & 2027

Create a premium account to unlock analyst estimates. Learn more

Dec '24 2025
Estimates
Revenue Million CHF 483.90 488.33
0.55% 0.92%
EBITDA Margin 16.62% 17.93%
10.15% 7.91%
Net Margin -1.53% 2.57%
2,580.43% 268.06%

2 Analysts have issued a sales forecast Medmix 2025 . The average Medmix sales estimate is

CHF488m
Unlock
. This is
0.92% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
CHF491m 1.38%
Unlock
, the lowest is
CHF486m 0.45%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 CHF484m 0.55%
2025
CHF488m 0.92%
Unlock
2026
CHF511m 4.56%
Unlock
2027
CHF542m 6.08%
Unlock

2 Analysts have issued an Medmix EBITDA forecast 2025. The average Medmix EBITDA estimate is

CHF87.5m
Unlock
. This is
8.89% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
CHF91.1m 13.31%
Unlock
, the lowest is
CHF84.0m 4.47%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 CHF80.4m 9.54%
2025
CHF87.5m 8.89%
Unlock
2026
CHF99.0m 13.08%
Unlock
2027
CHF116m 16.81%
Unlock

EBITDA Margin

2024 16.62% 10.15%
2025
17.93% 7.91%
Unlock
2026
19.39% 8.14%
Unlock
2027
21.35% 10.11%
Unlock

2 Medmix Analysts have issued a net profit forecast 2025. The average Medmix net profit estimate is

CHF12.6m
Unlock
. This is
269.59% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
CHF15.7m 312.43%
Unlock
, the lowest is
CHF9.4m 226.76%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 CHF-7.4m 2,566.67%
2025
CHF12.6m 269.59%
Unlock
2026
CHF24.0m 91.47%
Unlock
2027
CHF36.8m 53.27%
Unlock

Net Margin

2024 -1.53% 2,580.43%
2025
2.57% 268.06%
Unlock
2026
4.71% 83.27%
Unlock
2027
6.80% 44.37%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 & 2027

Create a premium account to unlock analyst estimates. Learn more

Dec '24 2025
Estimates
Earnings Per Share CHF -0.18 0.31
1,900.00% 272.22%
P/E 34.18
EV/Sales 1.32

2 Analysts have issued a Medmix forecast for earnings per share. The average Medmix EPS is

CHF0.31
Unlock
. This is
247.62% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
CHF0.39 285.71%
Unlock
, the lowest is
CHF0.23 209.52%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 CHF-0.18 1,900.00%
2025
CHF0.31 272.22%
Unlock
2026
CHF0.59 90.32%
Unlock
2027
CHF0.90 52.54%
Unlock

P/E ratio

Current -50.10 103.08%
2025
34.18 168.23%
Unlock
2026
17.86 47.75%
Unlock
2027
11.65 34.77%
Unlock

Based on analysts' sales estimates for 2025, the Medmix stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 1.33 27.32%
2025
1.32 0.54%
Unlock
2026
1.27 4.36%
Unlock
2027
1.19 5.73%
Unlock

P/S ratio

Current 0.91 33.87%
2025
0.90 0.91%
Unlock
2026
0.86 4.37%
Unlock
2027
0.81 5.72%
Unlock

Current Medmix Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
RESEARCH PARTNERS AG
Locked
Locked
Locked Feb 26 2025
Analyst Rating Date
Locked
RESEARCH PARTNERS AG:
Locked
Locked
Feb 26 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today